News | October 28, 2007

Boston Scientific Carotid Artery Stenting Trials Produce Positive Three-Year Results

October 29, 2007 - Boston Scientific Corp. announced positive three-year results from its CABERNET and BEACH carotid artery stenting clinical trials, which evaluated the effectiveness of stenting with embolic protection for patients at high risk for carotid endarterectomy (CEA), the surgical treatment for carotid artery disease.

The three-year CABERNET and BEACH results were presented by L. Nelson Hopkins, M.D., Chairman of Neurosurgery, Department of Neurosurgery, State University of New York, Buffalo, NY, at the annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in Washington, D.C. Dr. Hopkins reported that the CABERNET major stroke rate was 1.3 percent at 30 days and 2.8 percent at three years. The reported BEACH major stroke rate was 1.7 percent at 30 days and 8.1 percent at three years. According to the three-year CABERNET data, the ipsilateral stroke rate (a stroke occurring on the treated side of the neck) was 2.9 percent at 30 days and by three years had only increased to 4.9 percent. In the BEACH trial, the ipsilateral stroke rate was 3.1 percent at 30 days and by three years had only increased to 7.7 percent.

"The three-year results suggest not only an immediate benefit for patients treated with Boston Scientific's NexStent Carotid Stent and FilterWire EZ Embolic Protection System, but also a longer-term benefit in reducing the incidence of stroke over time," said Dr. Hopkins, Co-Principal Investigator of the CABERNET and BEACH clinical trials. "In particular, the CABERNET three-year trial results are very encouraging and continue to demonstrate the long-term efficacy and durability associated with Boston Scientific's NexStent Carotid Stent when used with the Company's FilterWire EZ Embolic Protection System in treating patients at high risk for carotid endarterectomy."

The CABERNET clinical trial was designed to evaluate the safety and efficacy of Boston Scientific's NexStent Carotid Stent and FilterWire EZ Embolic Protection System, while the BEACH clinical trial was designed to evaluate the safety and efficacy of the Company's Carotid WALLSTENT Monorail Endoprosthesis and FilterWire EZ Embolic Protection System. CABERNET and BEACH were both prospective, non-randomized, single-arm clinical trials enrolling 454 patients and 480 patients, respectively, who were at high risk for CEA.

"We continue to be excited about the favorable results being reported from the CABERNET and BEACH trials now out to three years," said John Pedersen, President of Peripheral Interventions of Boston Scientific. "The three-year data provide further evidence of the benefits of the NexStent Carotid Stent and FilterWire EZ Embolic Protection System in treating patients at risk for stroke, as well as the potential clinical benefits of Carotid WALLSTENT Endoprosthesis. These trials are indicative of our commitment as a Company to evaluate the long-term safety and efficacy of our products in treating carotid artery disease."

The NexStent Carotid Stent is a closed cell, nitinol stent with a rolled sheet design that enables one stent size to adapt to multiple diameters in tapered or non-tapered vessel configurations. The Carotid WALLSTENT Endoprosthesis is a self-expanding stent with a braided, closed cell design. Closed-cell configurations are designed to increase lesion coverage and provide a smooth inner lumen to help facilitate delivery and retrieval of ancillary devices. The FilterWire EZ System -- an advanced technology designed for simplicity and effectiveness -- captures debris efficiently, simplifies filter sizing and is easy to deliver and retrieve. When compared to surgical alternatives, this system provides a less-invasive way to treat patients with carotid artery disease.

The U.S. FDA has approved the NexStent Carotid Stent and FilterWire EZ Embolic Protection System for use in patients with carotid artery disease who are at high risk for CEA. The Carotid WALLSTENT Endoprosthesis is an investigational device currently under FDA review and is subject to investigational use only under U.S. Federal law.

The carotid arteries, located on either side of the neck, are the main conduit for blood flow to the brain. Plaque formation in these arteries can lead to carotid occlusive disease, putting patients at risk for stroke. Stroke is the third leading cause of death in the United States, killing nearly 160,000 Americans every year, and is the leading cause of serious, long-term disability in the U.S.

For more information: http://www.bostonscientific.com/

Related Content

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Cardiovascular Clinical Studies | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init